Page 13 - 磁共振成像2024年7期电子刊

临床指南·专家共识
Clinlcal Guidelines & Expert Consensu 磁共振成像 2024年7月第15卷第7期 Chin J Magn Reson Imaging, Jul, 2024, Vol. 15, No. 7

449-459. DOI: 10.1097/01.rli.0000262089.55618.18. radiol.13131529.
[6] BARNES A, ALONZI R, BLACKLEDGE M, et al. UK quantitative [24] HILLENGASS J, USMANI S, RAJKUMAR S V, et al. International
WB-DWI technical workgroup: consensus meeting recommendations myeloma working group consensus recommendations on imaging in
on optimisation, quality control, processing and analysis of quantitative monoclonal plasma cell disorders[J/OL]. Lancet Oncol, 2019, 20(6):
whole-body diffusion-weighted imaging for cancer[J/OL]. Br J Radiol, e302-e312 [2024-01-14]. https://pubmed.ncbi.nlm.nih.gov/31162104/.
2018, 91(1081): 20170577 [2024-01-14]. https://pubmed.ncbi.nlm.nih. DOI: 10.1016/S1470-2045(19)30309-2.
gov/29076749/. DOI: 10.1259/bjr.20170577. [25] KUMAR S, PAIVA B, ANDERSON K C, et al. International Myeloma
[7] COSTELLOE C M, MADEWELL J E, KUNDRA V, et al. Conspicuity Working Group consensus criteria for response and minimal residual
of bone metastases on fast Dixon-based multisequence whole-body disease assessment in multiple myeloma[J/OL]. Lancet Oncol, 2016,
MRI: clinical utility per sequence[J]. Magn Reson Imaging, 2013, 17(8): e328-e346 [2024-01-14]. https://pubmed.ncbi.nlm.nih.gov/27511158/.
31(5): 669-675. DOI: 10.1016/j.mri.2012.10.017. DOI: 10.1016/S1470-2045(16)30206-6.
[8] COSTELLOE C M, KUNDRA V, MA J F, et al. Fast Dixon [26] WANG K W, LEE E, KENIS S, et al. Application of diffusion-weighted
whole-body MRI for detecting distant cancer metastasis: a preliminary whole-body MRI for response monitoring in multiple myeloma after
clinical study[J]. J Magn Reson Imaging, 2012, 35(2): 399-408. DOI: chemotherapy: a systematic review and meta-analysis[J]. Eur Radiol, 2022,
10.1002/jmri.22815. 32(4): 2135-2148. DOI: 10.1007/s00330-021-08311-z.
[9] REEDER S B, HU H H, SIRLIN C B. Proton density fat-fraction: a [27] EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New
standardized MR-based biomarker of tissue fat concentration[J]. J response evaluation criteria in solid tumours: revised RECIST guideline
Magn Reson Imaging, 2012, 36(5): 1011-1014. DOI: 10.1002/jmri.23741. (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.
[10] BALLON D, WATTS R, DYKE J P, et al. Imaging therapeutic ejca.2008.10.026.
response in human bone marrow using rapid whole-body MRI[J]. [28] 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国多发
Magn Reson Med, 2004, 52(6): 1234-1238. DOI: 10.1002/mrm.20291. 性骨髓瘤工作组 . 中国多发性骨髓瘤诊治指南(2011 年修订)[J]. 中
[11] TORKIAN P, MANSOORI B, HILLENGASS J, et al. 华内科杂志, 2011, 50(10): 892-896. DOI: 10.3760/cma.j.issn.0578-1426.
Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment 2011.10.028.
response assessment of multiple myeloma: a systematic review and Hematology Branch of the Chinese Medical Doctor Association,
meta-analysis[J]. Skeletal Radiol, 2023, 52(3): 565-583. DOI: 10.1007/ Hematology Branch of the Chinese Medical Association, Chinese
s00256-022-04119-0. Multiple Myeloma Working Group. Chinese Guidelines for the
[12] DUTOIT J C, VERSTRAETE K L. MRI in multiple myeloma: a Diagnosis and Treatment of Multiple Myeloma (Revised in 2022) [J].
pictorial review of diagnostic and post-treatment findings[J]. Insights Chin J Intern Med, 2011, 50(10): 892-896. DOI: 10.3760/cma.j.issn.0578-
Imaging, 2016, 7(4): 553-569. DOI: 10.1007/s13244-016-0492-7. 1426.2011.10.028.
[13] USMANI S Z, HEUCK C, MITCHELL A, et al. Extramedullary disease [29] DURIE B G, SALMON S E. A clinical staging system for multiple
portends poor prognosis in multiple myeloma and is over-represented in myeloma. Correlation of measured myeloma cell mass with presenting
high-risk disease even in the era of novel agents[J]. Haematologica, 2012, clinical features, response to treatment, and survival[J]. Cancer, 1975,
97(11): 1761-1767. DOI: 10.3324/haematol.2012.065698. 36(3): 842-854. DOI: 10.1002/1097-0142(197509)36:3<842:aid-cncr282036
[14] GAGELMANN N, EIKEMA D J, IACOBELLI S, et al. Impact of 0303>3.0.co;2-u.
extramedullary disease in patients with newly diagnosed multiple [30] PALUMBO A, AVET-LOISEAU H, OLIVA S, et al. Revised
myeloma undergoing autologous stem cell transplantation: a study from international staging system for multiple myeloma: a report from
the Chronic Malignancies Working Party of the EBMT[J]. Haematologica, international myeloma working group[J]. J Clin Oncol, 2015, 33(26):
2018, 103(5): 890-897. DOI: 10.3324/haematol.2017.178434. 2863-2869. DOI: 10.1200/JCO.2015.61.2267.
[15] TIRUMANI S H, SHINAGARE A B, JAGANNATHAN J P, et al. MRI [31] RASCHE L, ANGTUACO E J, ALPE T L, et al. The presence of large
features of extramedullary myeloma[J]. AJR Am J Roentgenol, 2014, focal lesions is a strong independent prognostic factor in multiple
202(4): 803-810. DOI: 10.2214/AJR.13.10856. myeloma[J]. Blood, 2018, 132(1): 59-66. DOI: 10.1182/blood-2018-04-
[16] 古雅雯, 吴颖, 颜瑞馨, 等 . 磁共振成像水脂分离技术在多发性骨髓 842880.
瘤 患 者 中 的 应 用 研 究 [J]. 中 国 实 验 血 液 学 杂 志 , 2022, 30(1): [32] MAI E K, HIELSCHER T, KLOTH J K, et al. A magnetic resonance
183-188. DOI: 10.19746/j.cnki.issn1009-2137.2022.01.030. imaging-based prognostic scoring system to predict outcome in
GU Y W, WU Y, YAN R X, et al. Application of MRI water-fat separation transplant-eligible patients with multiple myeloma[J]. Haematologica,
technology in patients with multiple myeloma[J]. J Exp Hematol, 2022, 2015, 100(6): 818-825. DOI: 10.3324/haematol.2015.124115.
30(1): 183-188. DOI: 10.19746/j.cnki.issn1009-2137.2022.01.030. [33] LEE S Y, KIM H J, SHIN Y R, et al. Prognostic significance of focal
[17] 裴晓姣, 潘振宇, 炼宇飞, 等 . 椎体骨髓脂肪含量比在新诊断多发性 lesions and diffuse infiltration on MRI for multiple myeloma: a
骨髓瘤中的诊断价值[J]. 中国全科医学, 2021, 24(20): 2601-2606. meta-analysis[J]. Eur Radiol, 2017, 27(6): 2333-2347. DOI: 10.1007/
DOI: 10.12114/j.issn.1007-9572.2021.00.557. s00330-016-4543-8.
PEI X J, PAN Z Y, LIAN Y F, et al. Predictive value of fat fraction [34] WALKER R, BARLOGIE B, HAESSLER J, et al. Magnetic resonance
quantification of lumbar spine for newly diagnosed multiple myeloma[J]. imaging in multiple myeloma: diagnostic and clinical implications[J]. J
Chin Gen Pract, 2021, 24(20): 2601-2606. DOI: 10.12114/j.issn.1007-9572. Clin Oncol, 2007, 25(9): 1121-1128. DOI: 10.1200/JCO.2006.08.5803.
2021.00.557. [35] MOULOPOULOS L A, DIMOPOULOS M A, KASTRITIS E, et al.
[18] DONG H Z, HUANG W Y, JI X D, et al. Prediction of early treatment Diffuse pattern of bone marrow involvement on magnetic resonance
response in multiple myeloma using MY-RADS total burden score, imaging is associated with high risk cytogenetics and poor outcome in
ADC, and fat fraction from whole-body MRI: impact of Anemia on newly diagnosed, symptomatic patients with multiple myeloma: a
predictive performance[J]. AJR Am J Roentgenol, 2022, 218(2): single center experience on 228 patients[J]. Am J Hematol, 2012,
310-319. DOI: 10.2214/AJR.21.26534. 87(9): 861-864. DOI: 10.1002/ajh.23258.
[19] ZHANG H B, XUE H D, ALTO S, et al. Integrated shimming improves [36] ZHANG L, WANG Q, WU X, et al. Baseline bone marrow ADC value
lesion detection in whole-body diffusion-weighted examinations of of diffusion-weighted MRI: a potential independent predictor for
patients with plasma disorder at 3 T[J]. Invest Radiol, 2016, 51(5): progression and death in patients with newly diagnosed multiple
297-305. DOI: 10.1097/RLI.0000000000000238. myeloma[J]. Eur Radiol, 2021, 31(4): 1843-1852. DOI: 10.1007/
[20] LARBI A, OMOUMI P, PASOGLOU V, et al. Whole-body MRI to s00330-020-07295-6.
assess bone involvement in prostate cancer and multiple myeloma: [37] WU C, HUANG J, XU W B, et al. Discriminating depth of response to
comparison of the diagnostic accuracies of the T1, short tau inversion therapy in multiple myeloma using whole-body diffusion-weighted
recovery (STIR), and high b-values diffusion-weighted imaging (DWI) MRI with apparent diffusion coefficient: preliminary results from a
sequences[J]. Eur Radiol, 2019, 29(8): 4503-4513. DOI: 10.1007/s00330- single-center study[J]. Acad Radiol, 2018, 25(7): 904-914. DOI:
018-5796-1. 10.1016/j.acra.2017.12.008.
[21] JI X D, HUANG W Y, DONG H Z, et al. Evaluation of bone marrow [38] ZHANG Y, XIONG X, FU Z Z, et al. Whole-body diffusion-weighted
infiltration in multiple myeloma using whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following
imaging and T1-weighted water-fat separation Dixon[J]. Quant bortezomib-based therapy: a large single-center cohort study[J/OL].
Imaging Med Surg, 2021, 11(2): 641-651. DOI: 10.21037/qims-20-289. Eur J Radiol, 2019, 120: 108695 [2024-01-14]. https://pubmed. ncbi.
[22] WANG Q, ZHANG L, LI S, et al. Histogram analysis based on nlm.nih.gov/31589995/. DOI: 10.1016/j.ejrad.2019.108695.
apparent diffusion coefficient maps of bone marrow in multiple [39] KOUTOULIDIS V, TERPOS E, PAPANIKOLAOU N, et al.
myeloma: an independent predictor for high-risk patients classified by Comparison of MRI features of fat fraction and ADC for early
the revised international staging system[J/OL]. Acad Radiol, 2022, treatment response assessment in participants with multiple myeloma[J].
29(6): e98-e107 [2024-01-14]. https://pubmed.ncbi.nlm.nih.gov/34452820/. Radiology, 2022, 304(1): 137-144. DOI: 10.1148/radiol.211388.
DOI: 10.1016/j.acra.2021.07.010. [40] RASCHE L, ALAPAT D, KUMAR M, et al. Combination of flow
[23] GILES S L, MESSIOU C, COLLINS D J, et al. Whole-body cytometry and functional imaging for monitoring of residual disease in
diffusion-weighted MR imaging for assessment of treatment response myeloma[J]. Leukemia, 2019, 33(7): 1713-1722. DOI: 10.1038/s41375-
in myeloma[J]. Radiology, 2014, 271(3): 785-794. DOI: 10.1148/ 018-0329-0.

·6 · https://www.chinesemri.com